2007 Law on Research

2007 Law on Research
Title	2007 Law on Research
Enacted by	National Assembly
Date enacted	2007
Status	in force

2007 Law on Research The 2007 Law on Research was a statutory framework enacted in 2007 to regulate scientific activity, institutional roles, and funding mechanisms across national research ecosystems. The law sought to harmonize relationships among universities such as Harvard University, University of Oxford, and Université Paris-Sorbonne; public agencies including the National Science Foundation, European Research Council, and Japan Society for the Promotion of Science; and industry partners like Siemens, Pfizer, and IBM. Provisions addressed ethical oversight, intellectual property rules tied to institutions such as the European Patent Office and United States Patent and Trademark Office, and coordination with international agreements including the Budapest Open Access Initiative, the Bayh–Dole Act, and the Lisbon Strategy.

Background and Legislative Context

The legislative origins trace to shifting policy debates involving actors like the Organisation for Economic Co-operation and Development, the World Health Organization, and national ministries such as the Ministry of Science and Technology (China), the Department for Business, Innovation and Skills (UK), and the United States Department of Energy. Precedents included statutes exemplified by the Bayh–Dole Act, directives from the European Commission, and recommendations from bodies such as the Royal Society and the National Academies of Sciences, Engineering, and Medicine. Political figures and policymakers including Angela Merkel, Tony Blair, and Barack Obama were referenced in debates alongside institutional reports from UNESCO, OECD, and the World Bank that shaped framing and adoption.

Key Provisions and Definitions

The statute defined terms referencing entities such as Massachusetts Institute of Technology, Stanford University, Max Planck Society, and CNRS; categorizations included basic research linked to institutes like Los Alamos National Laboratory and applied research associated with corporations like General Electric. It specified roles for units such as the National Institutes of Health, the Wellcome Trust, and the European Molecular Biology Laboratory and set parameters for projects aligned with initiatives like the Human Genome Project and the Large Hadron Collider. Definitions incorporated standards from organizations such as the International Organization for Standardization and ethical codes similar to those promoted by the Helsinki Declaration and the Nuremberg Code.

Institutional and Ethical Framework

The law established governance structures comparable to boards in Oxford University Press, councils like the Scientific Advisory Board, and regulatory agencies akin to the Food and Drug Administration and the European Medicines Agency. It mandated research ethics committees modeled on the Institutional Review Board and compliance with protocols referenced by World Medical Association and the Council for International Organizations of Medical Sciences. Institutional duties implicated stakeholders such as University of Tokyo, University of Cambridge, and ETH Zurich and required coordination with foundations like the Gates Foundation and the Rockefeller Foundation for ethical oversight and capacity building.

Funding, Intellectual Property, and Technology Transfer

Financial mechanisms aligned with funding bodies such as the Wellcome Trust, European Investment Bank, and the Canadian Institutes of Health Research, and procurement processes mirrored practices of DARPA and European Space Agency. Intellectual property clauses referenced systems at the European Patent Office, United States Patent and Trademark Office, and models exemplified by the Bayh–Dole Act and institutions like Stanford University's Office of Technology Licensing and the Korea Advanced Institute of Science and Technology. Technology transfer pathways involved intermediaries similar to Cambridge Enterprise, Kawasaki Heavy Industries, and Mitsubishi Heavy Industries and engagement with corporate partners including Microsoft, Google, and GlaxoSmithKline.

Implementation, Enforcement, and Compliance

Implementation duties were assigned to authorities comparable to the Ministry of Education, Culture, Sports, Science and Technology (Japan), national academies such as the Russian Academy of Sciences, and oversight agencies resembling the Government Accountability Office. Enforcement mechanisms drew on examples like the Antitrust Division (DOJ), tribunals akin to the European Court of Justice, and audit practices of institutions such as KPMG and Deloitte. Compliance reporting referenced models used by Nature, Science (journal), and standards set by the Committee on Publication Ethics and coordination with international treaties like the TRIPS Agreement.

Impact on Research Community and Industry

The law influenced universities and labs such as Princeton University, Columbia University, California Institute of Technology, and Brookhaven National Laboratory, and affected multinational corporations including Apple Inc., Bayer, and Toyota Motor Corporation. It shaped collaborations exemplified by consortia like CERN, Human Frontier Science Program, and International Thermonuclear Experimental Reactor and altered funding landscapes influenced by donors like the Simons Foundation and Howard Hughes Medical Institute. Career structures for researchers at institutions such as Imperial College London and the École Polytechnique Fédérale de Lausanne adapted to grant rules similar to those of the Marie Skłodowska-Curie Actions.

Amendments, Challenges, and Controversies

Subsequent amendments referenced legislative processes in bodies like the United States Congress, the European Parliament, and national assemblies such as the Knesset and the National People's Congress (China). Controversies involved debates similar to those around CRISPR-Cas9, stem cell research, and publishing disputes tied to Elsevier and Springer Nature, as well as litigation in venues like the United States Court of Appeals and arbitration under World Trade Organization mechanisms. Challenges invoked positions from groups such as Greenpeace, Doctors Without Borders, and Human Rights Watch and prompted policy responses from agencies like the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control.

Category:Research legislation